Article Text

PDF
Time to personalize the treatment of anti-MDA-5 associated lung disease
  1. Michael Lake,
  2. Gautam George,
  3. Ross Summer
  1. Division of Pulmonary and Critical Care, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA
  1. Correspondence to Dr Michael Lake, Division of Pulmonary and Critical Care Medicine, Thomas Jefferson University Hospital, Philadelphia PA 19107, USA; michael.lake{at}jefferson.edu

Statistics from Altmetric.com

We read with interest the article by the European League Against Rheumatism/American College of Rheumatology on the classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups.1 While we believe these criteria will help with the diagnosis of most of the major subgroups of idiopathic inflammatory myopathies, we anxiously await society guidelines that direct physicians on how best to individualise the treatment for specific subgroups of this disease.

For example, one subgroup we seek immediate direction is on the treatment of patients with antibodies directed against the melanoma differentiation associated protein 5 (anti-MDA5). This antibody is typically identified in patients with clinically amyopathic dermatomyositis (CADM), and it is now increasingly appreciated that some of these individuals …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles